CVKD Cadrenal Therapeutics
- 0.491
- +0.026+5.48%
- 0.510
- +0.020+3.98%
Cadrenal Therapeutics News
Favourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired Stock
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant...
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersAcrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.0% to $10.16 during Tuesday's regular session. The market value of their outstanding shares is at $230.0 million. BioSig Technologie
Express News | Cadrenal Therapeutics Shares Are Trading Higher After the Company Received FDA Orphan Drug Designation for Tecarfarin for the Prevention of Thromboembolism and Thrombosis in Patients With an Implanted Mechanical Circulatory Support Device
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients With LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant...
Express News | HC Wainwright & Co. Reiterates Buy on Cadrenal Therapeutics, Maintains $3 Price Target
Cadrenal Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/14/2024 411.95% HC Wainwright & Co. → $3 Reiterates Buy → Buy 12/18/2023 582.59% Noble Capital Markets
Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)
Cadrenal Therapeutics, Inc. (CVKD) Receives a Buy From Noble Financial
Cadrenal Therapeutics Files for $100M Mixed Shelf
A New Cause for Concern: Cadrenal Therapeutics, Inc. Adds a New Natural and Human Disruptions Risk
Cadrenal Therapeutics Announces Q4 2023 Operating Expenses Totaled $1.16M; Cash Used In Operating Activities Totaled $694,000 During Q4 2023; As Of December 31, 2023, Cash Balances Were $8.5M
Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, s
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersAgile Therapeutics (NASDAQ:AGRX) stock rose 82.4% to $1.81 during Thursday's pre-market session. The company's market cap stands at $5.3 million. Venus Concept (NASDAQ:VERO) stock rose 72.95% t
Cadrenal Therapeutics Announces Key Executive Appointment
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersSyra Health (NASDAQ:SYRA) shares rose 479.7% to $6.44 during Thursday's regular session. The company's market cap stands at $41.3 million. NanoString Technologies (NASDAQ:NSTG) stock moved upwa
Cadrenal Therapeutics Appoints Jeff Cole As Chief Operating Officer In Advance Of Tecarfarin Phase 3 Pivotal Trial >CVKD
Cadrenal Therapeutics Appoints Jeff Cole As Chief Operating Officer In Advance Of Tecarfarin Phase 3 Pivotal Trial >CVKD
TENX, PBM and PRSO Among Pre-market Losers
CTLT, BTAI and CAMP Are Among Pre Market Gainers
Analysis
Price Target
No Data
